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The carotenoid zeaxanthin is concentrated within the macula. Increased macular zeaxanthin is suggested to lower the risk of age-related macular
degeneration. The small red berry, wolfberry (Fructus barbarum L.; Gou Qi Zi and Kei Tze), is one of the richest natural sources of zeaxanthin.
However, carotenoid bioavailability is low, and food-based products with enhanced bioavailability are of interest. The present study investigated
zeaxanthin bioavailability from three wolfberry formulations. Berries were homogenised in hot (808C) water, warm (408C) skimmed milk and hot
(808C) skimmed milk, with freeze drying of each preparation into a powdered form. A zeaxanthin-standardised dose (15 mg) of each was con-
sumed, in randomised order, together with a standardised breakfast by twelve healthy, consenting subjects in a cross-over trial, with a 3–5-
week washout period between treatments. Blood samples were taken via a venous cannula immediately before (fasting) and 2, 4, 6, 7, 8 and
10 h post-ingestion. Zeaxanthin concentration in the triacylglycerol-rich lipoprotein fraction of plasma was measured by HPLC. Results
showed that triacylglycerol-rich lipoprotein zeaxanthin peaked at 6 h post-ingestion for all formulations. Zeaxanthin bioavailability from the
hot milk formulation was significantly higher (P,0·001) than from the others. Mean area under the curve (n 12) results were 9·73 (SEM 2·45),
3·24 (SEM 0·72) and 3·14 (SEM 1·09) nmol £ h/l for the hot milk, warm milk and hot water formulations, respectively. Results showed clearly
that homogenisation of wolfberry in hot skimmed milk results in a formulation that has a 3-fold enhanced bioavailability of zeaxanthin compared
with both the ‘classical’ hot water and warm skimmed milk treatment of the berries.
Wolfberry: Kei Tze: Gou Qi Zi: Chinese medicine: Macular degeneration: Zeaxanthin
Zeaxanthin is an oxygenated carotenoid (xanthophyll). Its diet-
ary intake is negatively associated with the incidence of some
cancers such as lung cancer (Le Marchand et al. 1993) and color-
ectal cancer (Slattery et al. 2000) as well as with the progression
of early atherosclerosis (Dwyer et al. 2004) or ischaemic stroke
(Polidori et al. 2002). Moreover, zeaxanthin also exerts a photo-
protective effect both in the skin (Gonzalez et al. 2003) and eye
(Rose et al. 1998). This photoprotective effect has been more
documented for the eye since zeaxanthin is concentrated
within the central area of the macula, or ‘yellow spot’, of the
eye (Landrum & Bone, 2001). Thinning of the macular pigment
accompanies ageing, and is associated with irretrievable loss of
central vision (Beatty et al. 1999; Hyman & Neborsky, 2002).
This condition is known as age-related macular degeneration
(AMD), and is currently the leading cause of blindness in
those aged over 65 years (Stokkermans, 2000; Landrum &
Bone, 2001; Mozaffarieh et al. 2003).
The underlying causes of AMD are not yet clear, but loss of
the protective macular pigment is suggested to accelerate oxi-
dative damage to the lipid-rich retina and so increase the risk
of AMD (Beatty et al. 2000). There is currently no effective
treatment for AMD (Curcio et al. 2000). Therefore, the focus
must be on preventing the onset and delaying progression of
macular degeneration. It is in this context that dietary caroten-
oids and their bioavailability are of importance, as it has been
suggested that increased intake of carotenoid-rich foods and
beverages may be a successful strategy in lowering the risk of
AMD (Moeller et al. 2000; Bartlett & Eperjesi, 2003; Krinsky
et al. 2003). Lutein, a structural isomer of zeaxanthin, has
been the carotenoid of interest in most studies to date (Landrum
et al. 1997; Olmedilla et al. 2001; Bartlett & Eperjesi, 2003;
Bone et al. 2003). However, lutein is found in the peripheral
areas of the macula, and zeaxanthin may be of more relevance
to AMD prevention owing to its central macular accumulation
(Handelman et al. 1988; Landrum et al. 1999; Bone et al. 2000).
In man, both zeaxanthin and lutein are obtained exclusively
from the diet. Foods that contain these carotenoids include kiwi
fruit, orange juice, melons, spinach, orange pepper and egg yolk
(Sommerburg et al. 1998; Benzie, 2003; Humphries & Khachik,
2003; Weller & Breithaupt, 2003). Fructus barbarum L., a small
red berry known variously as Gou Qi Zi, Kei Tze (Cantonese)
and wolfberry, is one of the richest plant sources of
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zeaxanthin (Lam & But, 1999; Zhou et al. 1999; Weller &
Breithaupt, 2003, Cheng et al. 2005). Wolfberry from Ningxia
province is commonly used in China in soups, tea, drinks, hot
pots, supplements and others. Wolfberry has a strong reputation
in Chinese culture as being beneficial for vision, as well as
being regarded as an anti-ageing traditional medicine that
addresses Yin deficiencies of liver and kidney, a condition that
is associated with diabetes in Chinese medicine (Bai, 1999;
Lam & But, 1999; Cheng et al.2005). Wolfberries are usually pur-
chased in a semi-dried form and are similar in size and texture to a
raisin. Although high, the zeaxanthin content of dried wolfberries
varies widely, with values reported as 11·5–43·3mg/g (Lam &
But, 1999), 194mg/g (Cheng et al. 2005), 300mg/g (Leung et al.
2001) and 820mg/g (Weller & Breithaupt, 2003). In comparison,
spinach, maize and squash generally contain,3mg/g (Sommer-
burg et al. 1998; Humphries & Khachik, 2003). The wide vari-
ation in zeaxanthin content of wolfberry is probably caused by
different growing, drying and storage conditions, as well as intrin-
sic differences in quality of the berries and perhaps differences in
methods used for measurement of zeaxanthin.
Zeaxanthin is lipophilic and most zeaxanthin in foods,
including wolfberry, is in the dipalmitate ester form (Zhou
et al. 1999; Weller & Breithaupt, 2003). However, xantho-
phyll esters are hydrolysed during the digestive process, and
newly absorbed zeaxanthin is incorporated within the chylo-
micron component of triacylglycerol-rich lipoproteins
(Pe´rez-Ga´lvez et al. 2003). Therefore, in assessing bioavail-
ability of dietary zeaxanthin, studying the post-ingestion
response in terms of the zeaxanthin content of triacylgly-
cerol-rich lipoproteins harvested from plasma is an appropriate
approach, and is preferable to measuring post-ingestion
changes in whole plasma zeaxanthin concentration. This lipo-
protein content approach can also be used to compare the
bioavailability of zeaxanthin in different foods or food
extracts, and to evaluate carotenoid-containing formulations
designed to have enhanced bioavailability.
Therefore, the aim of the present study was to compare the
bioavailability of zeaxanthin in different wolfberry-based for-
mulations in a human intervention trial. Two formulations
were milk-based, the difference between them being the tem-
perature at which homogenisation of the berries was carried
out. The third emulated the ‘classical’ hot water treatment
of the berries and this acted as the control treatment.
Materials and methods
The present study was a double-blinded, controlled, human
intervention trial of multiple cross-over design. The study
was granted ethical approval by The Hong Kong Polytechnic
University (Kowloon, Hong Kong). All subjects gave written
informed consent, and all procedures involving human sub-
jects complied with the Declaration of Helsinki as revised in
2000. Subject recruitment, intervention, sample collection
and laboratory work were all performed at The Hong Kong
Polytechnic University.
Subjects
Recruitment of subjects was by poster and word of mouth.
A total of nineteen subjects volunteered for the study. In
pre-study testing, fasting plasma lipids, plasma glucose,
blood Hb, blood pressure, pulse rate, weight and height
were measured. Sixteen subjects met all our inclusion criteria,
which were as follows: no evidence of diabetes; hyperlipidae-
mia or anaemia; not obese or overweight; non-smoker; not
hypertensive; not a regular user of food supplements or
aspirin; no history of serious or chronic disease. In the early
stages of the study, four subjects withdrew for personal
reasons or because of difficulty in drawing blood. Twelve sub-
jects (seven women (all non-pregnant throughout the trial) and
five men) completed the study. All subjects were Chinese, in
good general health and aged between 21 and 30 years of age.
To minimise the drop-out rate, volunteers were carefully
counselled on the details and frequency of the sample collec-
tion. Subjects were contacted by email and phone at least
weekly between treatments, and were contacted the day
before each treatment. On study days the subjects were closely
supervised to ensure their welfare and to facilitate their contin-
ued participation.
Study design
All twelve subjects took all three zeaxanthin-containing formu-
lations (designated as treatments A, B and C). Each treatment
was taken on a separate day. The elimination half-life of zeax-
anthin in plasma has been estimated to be about 14 d (Hartmann
et al. 2004). Therefore, each treatment day for each subject was
at least 3 weeks (but no more than 5 weeks) apart in order to
avoid treatment carry-over effects. The order of treatment for
each subject was arranged according to a William’s latin
square to ensure against an order effect. Each zeaxanthin treat-
ment was given in conjunction with a standard, fat-containing
breakfast to facilitate absorption.
Treatments
The A, B and C wolfberry formulations were supplied by
Nestle´ Research Center (Lausanne, Switzerland), and were
provided in labelled (as A, B or C), sealed aluminium foil
sachets, each containing a single, pre-weighed dose of
powder containing the same amount (15 mg) of zeaxanthin.
Formulation A contained wolfberries that had been homogen-
ised in skimmed milk at 808C; formulation B contained wolf-
berries that had been homogenised in skimmed milk at 408C;
formulation C contained wolfberries that had been ground and
heated in water at 808C. All berries used in the preparation of
these formulations were from the same batch produced in
Ningxia Province, China in summer 2003. On study days,
the appropriate sachets were opened and the entire contents
of one sachet were mixed with the rice porridge part of a stan-
dard meal, which was then served and eaten within 10 min.
The meal was prepared as follows: 50 g dehydrated rice
flakes (LongDi Co, Shenyang, China) were mixed with
250 ml hot water to which 10 g groundnut oil (Knife Brand
pure groundnut oil; Lam Soon, Hong Kong; the same batch
of oil was used throughout the study, but a newly opened
bottle was used each time) and 12 ml liquid seasoning
(Maggi Dongguan Ltd, China) were added, with the same
bottle of seasoning used throughout the study. The appropriate
pre-weighed powder constituting treatment A, B or C was then
mixed with the rice porridge, and the meal was served
immediately thereafter and eaten within 10 min. One standard
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slice of white bread (purchased from a local shop) and a cup
(200 ml) of warm water were also served. Volunteers were
instructed to use the bread to mop up all remaining liquid in
the bowl after the rice porridge had been eaten. No other
food or drink (except water, which was allowed in unlimited
amounts) was allowed until after the 10 h post-ingestion
blood sample was collected.
Blinding
Treatments and subjects were coded. Volunteers and the mem-
bers of the project team collecting and processing the blood
samples were blinded to the identity of each treatment. Fur-
thermore, the project personnel performing the laboratory
and data analyses were blinded as to which treatment (A, B
or C) was given on each treatment day.
Procedure on each study day
Subjects were requested to arrive fasting. For each subject, an
in-dwelling venous cannula was fitted and a fasting venous
blood sample was collected into commercial EDTA blood col-
lection tubes. This was designated the ‘0’ time sample. A
freshly prepared standard meal containing 15 mg zeaxanthin
in one of the three formulations was then served to each sub-
ject, and this was eaten within 10 min. Additional blood
samples were collected at 2, 4, 6, 7, 8 and 10 h post-ingestion,
via the in-dwelling cannula. After collection, blood samples
were immediately placed in the dark and at 48C. In conditions
of dim light, plasma was separated from cells after centrifu-
gation (48C, 10 min at 1000 g). EDTA plasma was sampled
and immediately placed at 2808C for storage for later harvest-
ing of the triacylglycerol-rich fraction and zeaxanthin
measurement. Subjects were closely supervised during each
study day in order to ensure they ate all the breakfast, that
they did not eat anything else, and to check their wellbeing.
After the 10 h blood sample was collected and the cannula
removed, the subjects were provided with a meal and a soft
drink.
Harvesting of triacylglycerol-rich lipoproteins for zeaxanthin
measurement
The extraction of the triacylglycerol-rich fraction from EDTA
plasma was modified from the method performed by Terpstra
(1985). Samples were processed in sets; each set comprised all
seven plasma samples (0 time, 2, 4, 6, 7, 8, 10 h post-inges-
tion) for one treatment for one subject. For harvesting of the
triacylglycerol-rich fraction, freshly thawed EDTA plasma
(2 ml) was mixed gently with KBr (450 mg), sucrose (50 mg)
and ethylene glycol (200ml). The mixture was then overlaid
sequentially with 500ml KBr (1·225 kg/l), 500ml KBr
(1·100 kg/l) and 1300ml Milli-Q water in an OptiSeal tube.
As much as possible of the triacylglycerol-rich fraction (the
top layer, and representing the triacylglycerol-rich fraction
of 2 ml plasma) was isolated after ultracentrifugation at 49
000 g, 20 8C for 15 min (Beckman Ultracentrifuge with rotor
TLA 100.4; Beckman Coulter, Inc., Fullerton, CA, USA).
Zeaxanthin was measured by a reverse-phase HPLC tech-
nique and employing a UV detection system. Reagents were
as follows: the zeaxanthin calibrator was purchased from
Indofine Chemical Company Inc. (Hillsborough, NJ, USA);
the internal carotenoid standard (IS) was from Chromsystems
Instruments and Chemicals GmbH (Munich, Germany);
methanol, absolute ethanol, tetrahydrofuran (THF) and
hexane (all Chromosolve for HPLC) were from Riedel-de
Haen (Sigma-Aldrich Laborchemikalien GmbH, Seelze,
Germany); butylated hydroxytoluene (BHT), ethylene
glycol, sucrose, KBr and ethylene-diamine tetraacetic acid
di-sodium dihydrate (EDTA-Na2.2H2O) were from Sigma
(St Louis, MO, USA); ascorbic acid and a-tocopherol were
from E. Merck (Darmstadt, Germany); acetonitrile (HiperSolv
for HPLC) was from BDH Laboratory Supplies (Poole,
Dorset, UK). The tubes for ultracentrifugation, OptiSeal
tubes (capacity 4·7 ml), were obtained from Beckman Coulter,
Inc. Falcon polypropylene tubes (15 ml, 17 £ 120 mm, with
screwed cap) for extraction were from Becton Dickinson
and Company (Franklin Lakes, NJ, USA). Milli-Q water
was made with a Millipore ultra-pure water system (Millipore
Corp., Bedford, MA, USA).
For calibration, a stock solution (879·0mmol/l) of zeax-
anthin was first prepared in 0·1 % (w/v) BHT–THF containing
a-tocopherol (8·8 mmol/l). With dilutions (in 0·1 % (w/v)
BHT–ethanol) of this stock solution, a working solution con-
taining zeaxanthin (17·6mmol/l) was made up in 0·1 % (w/v)
BHT–ethanol containing a-tocopherol (1 mmol/l). A working
solution of IS was made by diluting 1:25 (v/v) of original IS
solution with 0·1 % (w/v) BHT–ethanol.
Preparation of calibrators, pooled plasma and controls
All preparations involving BHT and THF were made freshly
as needed. Strong light was avoided during preparations of
calibrators and samples. From the working solution of zeax-
anthin (17·6mmol/l), various concentrations of zeaxanthin
(0–0·211mmol/l) were freshly and serially diluted with Dilu-
ent 1, which was a solution of 20:80 (v/v) of 0·1 % (w/v)
BHT–THF to Diluent (1:20 (v/v) of 0·1 % w/v aqueous
EDTA-Na2.2H2O to mobile phase, the solution filtered
through a 0·22mm Millipore membrane). By spiking suitable
amounts of each prepared zeaxanthin solution together with
IS working solution (100ml) into Milli-Q water, these final
solutions, referred to calibrators, were used to construct the
calibration curve.
The pooled plasma for controls was obtained from healthy
human subjects. Venous blood from the antecubital vein of
consenting volunteers was collected into commercially avail-
able heparinised tubes, chilled in ice-water and kept in the
dark until plasma was separated from cells. Separation of
plasma from blood was performed by centrifugation at
2500 g, 4 8C, for 10 min. Some of this was sampled and
stored at 280 8C and was used as a ‘normal’ plasma control.
The rest was used to prepare a ‘high’ plasma control: zeax-
anthin was spiked into this plasma, which was then sampled
and stored at 280 8C.
For extraction of zeaxanthin in calibrators, triacylglycerol-
rich fractions and plasma controls, the extraction procedure
was based on that of Aebischer et al. (1999). A 100ml
sample of the diluted zeaxanthin working solution was first
mixed in a Falcon tube with 500ml Milli-Q water containing
100ml 0·1 % (w/v) aqueous ascorbic acid. To this
solution, 100ml IS working solution was added and mixed,
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followed by the addition of 300ml ethanol. The mixture was
again hand-shaken to mix and 1000ml hexane containing
BHT (a 0·1 % (w/v) solution) was added. The tube containing
the mixture was rolled for 30 min on a horizontal mixer,
Denley Spiramix 5 (Denley Instruments Ltd, Billingshurst,
West Sussex, UK). The suspension was then centrifuged at
830 g, 4 8C, for 10 min. An 800ml sample of hexane (upper
layer) containing the extracted zeaxanthin was withdrawn
and evaporated to dryness at about 45 8C under a slow
stream of N2. The dry residue was temporarily stored in an
ice-water-bath and protected from light. The residue was vor-
texed (5 s), first with 20ml THF (containing 0·1 % (w/v)
BHT), followed by the addition of 80ml Diluent. The mixture
was again well vortexed (10 s) in order to re-dissolve the resi-
due. These extraction procedures were repeated for the
remaining calibrators. For the triacylglycerol-rich fractions,
the same procedures mentioned earlier were repeated, except
that the entire triacylglycerol-rich fraction harvested from
2 ml plasma was used in place of 100ml diluted zeaxanthin
working solution and 500ml Milli-Q water. For the controls,
the low or high control (100ml) was used in place of the
diluted zeaxanthin working solution. Finally, each extracted
calibrator, sample or control (80ml) was injected into the
HPLC system.
The HPLC chromatography system used included an Alliance
2695 Separations Module with temperature-controlled column
chamber and autosampler (Waters, Milford, MA, USA),
Waters 2996 Photodiode Array Detector and Waters Empower
Pro PDA software (version 5.00.00.00), a reversed-phase
Waters Symmetry, C18, analytical column (5mm, 250 £
4·6 mm internal diameter; Waters Corp., Milford, MA, USA)
and a cartridge guard column (Waters Sentry Guard column
with titanium frits, Symmetry, C18, 5mm, 20 £ 3·9 mm internal
diameter, also from Waters Corp.). The mobile phase was 0·1 %
(w/v) BHT in acetonitrile, which was filtered and degassed
through a Millipore membrane (type GV, pore size 0·22mm,
Millipore Corp.) before use. The detection was set at 450 nm.
The flow rate was time-programmed at two speeds; 1·0 ml/min
for 0–17 min; 2·5 ml/min for 18–60 min. The columns worked
under room temperature but the cooling chamber of the autosam-
pler was set at 4 8C.
Peak areas of zeaxanthin and IS were recorded from each
chromatogram. By plotting the area ratio of the peak area of
zeaxanthin to that of IS against concentration of calibrator
spiked (i.e. zeaxanthin spiked into water), a calibration
curve for zeaxanthin could be constructed. The
equivalent standard concentration (mmol/l) of zeaxanthin in
each sample was calculated by dividing the area ratio
(zeaxanthin:IS in the sample) with the slope of the calibration
curve. Hence, the zeaxanthin concentration (mmol/l) of the
blood sample was deduced by multiplying the equivalent
zeaxanthin standard concentration (mmol/l) with the volume
(ml) of zeaxanthin standard used (which was 100ml) and
divided by the volume (ml) of the blood sample used for the
triacylglycerol-rich fraction extraction (2 ml).
The linear range was determined by direct injections of
standards at various concentrations. Linearity of response was
assessed from the coefficient of correlation (r) of the regression
line. Seven replicates of a calibrator (0·053mmol/l) were used to
assess the within-day precision. The slopes from 10-consecu-
tive-day assays were used to assess the between-day precision.
Diluted solutions of the standard were injected in sequence of
decreasing concentrations to measure the detection limit. The
signal:noise ratio was at least 2:1 for the limit. For estimation
of recovery, Milli-Q water was spiked with zeaxanthin standard
(100ml 0·053mmol/l) and the IS working standard solution
(100ml), extracted and then assayed (n 7). By comparing with
direct injections of an equivalent amount of pure
zeaxanthin standard and the IS solution (n 7), recovery was
assessed. All samples for zeaxanthin measurement were pro-
tected from light at all times, owing to the light-sensitive
nature of zeaxanthin.
Statistical analysis
A key variable of interest in the present study was the 0–10 h
area under the curve (AUC; 0–10 h; nmol £ h/l) of zeax-
anthin. This was calculated for each subject by using trapezoi-
dal approximation. Both the total AUC and the baseline-
adjusted AUC (corrected for zeaxanthin detected in the fasting
samples) are presented. The maximum concentration and the
time to reach maximum concentration were also estimated.
The 0–10 h AUC values for zeaxanthin in the triacylgly-
cerol-rich fraction (expressed as nmol/l plasma) were com-
pared across treatments using ANOVA with Neuman–Keuls
multiple comparison post test using GraphPad Prism version
4.0 for Windows (GraphPad Software Inc., San Diego, CA,
USA), and P,0·05 was considered statistically significant.
Results
The CV for the within-day and between-day precision for zeax-
anthin measurements were, respectively, 2·9 and 4·1 %. In
regard to the limit of detection, this assay could detect down to
an amount of 0·35 pmol zeaxanthin injected (peak area of
about 2000mV £ s or signal:noise ratio of 2:1 or greater). This
is equivalent to 0·11 nmol zeaxanthin/l plasma of 2 ml sample
size. The recovery of zeaxanthin when extracted from water
was 97 %. A representative chromatogram is shown in Fig. 1.
The mean responses to each treatment in terms of AUC 0–
10 h and maximum concentration values for the twelve sub-
jects are presented in Table 1, and the responses by time
and treatment are shown in Fig. 2. It can be seen that the
response to treatment A (the hot milk formulation) was
about two to three times higher than the response to both treat-
ments B (warm milk formulation) and C (hot water formu-
lation), both of which were similar to each other. The time
to maximum response overall was at 6 h, but this varied
slightly between subjects.
Variation in response was quite wide, and four of the sub-
jects (three females and one male) showed a very poor
response to zeaxanthin ingestion. Therefore the data were
reanalysed excluding these subjects. Excluding the poor
responders did not change the ranking of treatment response
seen with the twelve subjects (A . B ¼ C).
Discussion
Effective nutritional strategies to promote functional longevity in
our ageing communities would have a significant socio-economic
impact globally. One strategy may be to increase zeaxanthin
intake since it has been suggested that this might lead to
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preservation of the macular pigment with prevention or delay of
age-related maculopathy, to decrease cancer incidence and to
reduce early atherosclerosis and ischaemia (Hammond et al.
1997; Mares-perlman et al. 2002). However, the bioavailability
of zeaxanthin, and other carotenoids, is low and variable, and is
affected by food structure, extraction of nutrients from food,
concomitant lipid intake, the type and form of carotenoid, and
interaction with other carotenoids or nutrients (Parker et al.
1999; van het Hof et al. 2000). Therefore, care must be taken
when designing or choosing carotenoid supplements, and bioa-
vailability is a key factor to consider. ‘Traditional’ means of
food extraction have often employed hot water. However, this
Table 1. Summary of results for twelve subjects treated with three different formulations of wolfberry (Fructus barbarum L.) containing 15mg
zeaxanthin
(Mean values with their standard errors and 95% confidence intervals)
Cmax (nmol/l) AUC (nmol £ h/l)
AUC adjusted for baseline
(nmol £ h/l)
Treatment Mean SEM 95% CI Mean SEM 95% CI Mean SEM 95% CI
A (skimmed milk, 808C formulation) 1·72 0·46 0·81, 2·62 9·73 2·45 4·33, 15·14 9·73 2·45 4·33, 15·14
B (skimmed milk, 408C formulation) 0·75 0·21 0·33, 1·17 4·91* 1·64 1·69, 8·12 3·24** 0·72 1·66, 4·82
C (hot water, 808C formulation) 0·69 0·21 0·28, 1·10 4·39* 1·30 1·84, 6·94 3·14** 1·09 0·75, 5·54
Cmax, maximum concentration; AUC, area under the curve.
Mean value was significantly different from that for treatment A: *P,0·005, **P,0·001.
For details of subjects and procedures, see p. 155.
A
U
–0.0010
–0.0008
–0.0006
–0.0004
–0.0002
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
0.0012
0.0014
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
13
. 4
35
28
. 1
10
Fig. 1. Representative chromatogram of an extract of the triacylglycerol-rich lipoprotein fraction of blood plasma (blood sample collected after ingestion
of zeaxanthin-containing supplement) showing the zeaxanthin peak at 13·435min and the internal standard peak at 28·110min. AU, arbitrary units. For details of
subjects and procedures, see p. 155.
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Fig. 2. Zeaxanthin concentration in triacylglycerol-rich lipoprotein fraction of blood plasma collected before and up to 10 h post-ingestion of 15mg zeaxanthin in
each of three different formulations as follows: A (hot skimmed milk formulation; B); B (warm skimmed milk formulation; O); C (hot water formulation; X). Results
are means of twelve subjects, with standard errors of the mean represented by vertical bars. For details of subjects and procedures, see p. 155.
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may leave bioactive components unextracted. Whey protein for-
mulation has been reported to improve bioavailability of lycopene
(Richelle et al. 2002). The present study has shown the effect of
formulation and processing of a carotenoid-rich food on zeax-
anthin bioavailability.
It was noticeable that the hot and warm milk-based formu-
lations were, respectively, orange and red in colour. This
difference may reflect a different interaction between zeax-
anthin and other biopolymers. In practice we conclude that
in the presence of milk proteins, the higher temperature of
processing enhances zeaxanthin bioavailability of wolfberry,
presumably by improving its incorporation into mixed
micelles, uptake by enterocytes and subsequent release in tria-
cylglycerol-rich lipoproteins. The exact mechanism for the
enhancement of bioavailability is still unclear and is the
object of on-going research. However, it is worth noting that
the enhanced bioavailability was not due to additional fat
ingestion, as skimmed milk was used in both milk-based
formulations.
Previously published human studies that have investigated
plasma zeaxanthin to single-dose ingestion or supplementation
have used eggs (Handelman et al. 1999), purified non-esterified
zeaxanthin (Hartmann et al. 2004), zeaxanthin extracted from
wolfberry in esterified and non-esterified forms (Breithaupt
et al. 2004), and whole wolfberries (Cheng et al. 2005). Inges-
tion of eggs has the disadvantage of increasing LDL-cholesterol,
with a concomitant increase in CHD risk (Verschuren et al.
1995), and attention is worth focusing on other natural sources
of zeaxanthin. However, there is only one previous study
(Pe´rez-Ga´lvez et al. 2003) that has investigated the bioavailabil-
ity of zeaxanthin in terms of the triacylglycerol-rich lipoprotein
response. In an uncontrolled study of nine subjects, Pe´rez-
Ga´lvez et al. (2003) studied chylomicron zeaxanthin content
after ingestion of paprika oleoresin containing 5·3 mg zeax-
anthin (and ingested along with bread and 5 g oil) in the esterified
form. Results showed that response peaked at 6 h post-ingestion,
as was found in the present study. The mean maximum chylomi-
cron zeaxanthin concentration was 5·73 (SEM 1·14) nmol/l
plasma, and the 0–12 h AUC was 32·3 (SEM 1·12) nmol £ h/l.
The two other acute-response studies (Breithaupt et al. 2004;
Hartmann et al. 2004) monitored whole plasma response, and
comparison with response in triacylglycerol-rich fraction of
plasma is not meaningful.
Populations consist of low to high carotenoid absorbers, and
as a result all studies performed to date, including the present
one, have shown a very large inter-individual variation in
response. In the present study, four subjects gave a very
poor or even undetectable response to zeaxanthin ingestion.
However, the rank order of zeaxanthin bioavailability from
the different treatments was the same whether or not this
was taken into account. This large inter-individual variability
might be explained by pre-existing zeaxanthin status or by
other factors such as expression and activity of transporters.
Indeed, it has been recently demonstrated in Caco-2 TC-7
cells (Reboul et al. 2005) that lutein is not only absorbed by
passive diffusion but also by facilitated transport processes.
These transporters, which are also implicated in the transport
of other lipid-soluble materials, are known to be present in
various polymorphic forms in man (Hubacek et al. 2004;
Miwa et al. 2005; Puddu et al. 2005; Woll et al. 2005).
This may affect absorption efficiencies, probably explaining
the highly variable inter-individual absorption seen. Further
work is needed in this area of nutrigenomics.
In summary, the new data presented here show that the bioa-
vailability of zeaxanthin in a natural product (wolfberry) can be
enhanced three-fold by homogenisation of the berries in hot
skimmed milk. This is of relevance to nutrition and to human
health because it is suggested that increased dietary intake of
zeaxanthin may help maintain the macular pigment and, thereby,
lower the risk of AMD, an increasingly common, irreversible
and largely untreatable cause of visual disability. In this
regard, a food supplement from a natural source that has an
enhanced zeaxanthin bioavailability is of interest and potential
benefit. The question of the efficacy of increased zeaxanthin
intake in terms of macular pigment density and AMD prevention
is an interesting and potentially valuable area of research that can
only be answered by long-term supplementation studies using
zeaxanthin-containing supplements of enhanced bioavailability,
such as the one described in the present study.
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